Additionally, Canagliflozin has been shown to upregulate BRCA1 while suppressing mTOR‐mediated inflammatory and pyroptotic signaling, reinforcing its therapeutic potential in breast cancer management [68]. This evidence concerns the gene MTOR and breast cancer.